文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症复苏、休克与脓毒症

连续性肾脏替代治疗患者低体温发生率及相关因素分析

[Analysis of the incidence and related factors of hypothermia in patients with continuous renal replacement therapy].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2023-01-01
一句话结论AKI患者CRRT期间低体温发生率高,透析液加热组低体温发生率显著低于反向管路加热组(40.5% vs 69.4%),休克、中高剂量血管活性药、反向管路加热及CRRT治疗剂量为低体温危险因素,MAP为保护因素。

该前瞻性研究纳入2020年1月至2022年12月皖南医学院第一附属医院(弋矶山医院)重症医学科收治的73例接受CRRT的AKI患者,随机分为透析液加热组(37℃透析机加热板,37例)与反向管路加热组(Prismaflex CRRT系统Barkey血液加热器,加热线温度41℃,36例),持续监测体温。透析液加热组低体温发生率显著低于反向管路加热组[40.5%(15/37)vs. 69.4%(25/36),P<0.05],且低体温发生时间更晚(5.40±0.92 h vs. 3.35±0.92 h,P<0.01)。多因素Logistic回归显示休克、中高剂量血管活性药、反向管路加热、CRRT治疗剂量为低体温危险因素,MAP为保护因素。作者认为加热CRRT治疗液可有效降低低体温发生率。

要点

  • 透析液加热组低体温发生率40.5%(15/37)显著低于反向管路加热组69.4%(25/36),P<0.05;低体温发生时间透析液加热组5.40±0.92 h晚于反向管路加热组3.35±0.92 h,P<0.01
  • 多因素Logistic回归:休克OR=17.633(95%CI 1.487-209.064)、中高剂量血管活性药OR=24.320(95%CI 3.076-192.294)、反向管路加热OR=13.316(95%CI 1.485-119.377)、CRRT治疗剂量OR=1.130(95%CI 1.020-1.251)为低体温危险因素,均P<0.05
  • MAP为低体温保护因素(OR=0.922,95%CI 0.861-0.987,P<0.05);低体温组MAP 77.45±12.47 mmHg低于非低体温组94.42±14.51 mmHg,P<0.01
  • 低体温组休克45.0%(18/40)vs. 非低体温组6.1%(2/33)、中高剂量血管活性药82.5%(33/40)vs. 18.2%(6/33)、CRRT治疗剂量51.50±9.38 vs. 38.42±10.97 mL×kg-1×h-1,均P<0.05
  • 作者认为加热CRRT治疗液可有效降低AKI患者CRRT期间低体温发生率;中高剂量血管活性药定义:中剂量0.2-0.5 μg×kg-1×min-1,高剂量>0.5 μg×kg-1×min-1

适用人群与场景

  • 2020年1月至2022年12月皖南医学院第一附属医院(弋矶山医院)重症医学科收治的接受CRRT的急性肾损伤(AKI)患者,最终纳入73例,透析液加热组37例、反向管路加热组36例

诊断标准与关键阈值

  • 低体温定义:体温低于36℃或较基础体温下降超过1℃

处置流程与药物剂量

  • 两组均由床旁医师根据患者具体情况提供合理的治疗模式和参数设置
  • 透析液加热组:使用旭化成(AsahiKASEI)透析机加热板将透析液加热至37℃
  • 反向管路加热组:使用Prismaflex CRRT系统的Barkey血液加热器加热透析液,加热线温度设为41℃
  • 持续监测患者体温,比较两组低体温发生率和持续时间

研究设计与关键结果

  • 前瞻性研究,纳入73例接受CRRT的AKI患者,随机数字表法分为透析液加热组(37例)和反向管路加热组(36例)
  • 透析液加热组低体温发生率显著低于反向管路加热组[40.5%(15/37)vs. 69.4%(25/36),P<0.05],低体温发生时间晚于反向管路加热组(5.40±0.92 h vs. 3.35±0.92 h,P<0.01)
  • 按是否发生低体温分为低体温组(n=40)和非低体温组(n=33):低体温组MAP 77.45±12.47 mmHg低于非低体温组94.42±14.51 mmHg(P<0.01);休克45.0%(18/40)vs. 6.1%(2/33)、中高剂量血管活性药82.5%(33/40)vs. 18.2%(6/33)、CRRT治疗剂量51.50±9.38 vs. 38.42±10.97 mL×kg-1×h-1,均P<0.05;低体温组以输液线加热为主62.5%(25/40),非低体温组以透析液加热为主66.7%(22/33),P<0.05
  • 二元多因素Logistic回归:休克OR=17.633(95%CI 1.487-209.064)、中高剂量血管活性药OR=24.320(95%CI 3.076-192.294)、CRRT加热类型(反向管路加热)OR=13.316(95%CI 1.485-119.377)、CRRT治疗剂量OR=1.130(95%CI 1.020-1.251)为低体温危险因素(均P<0.05),MAP为保护因素(OR=0.922,95%CI 0.861-0.987,P<0.05)

证据类型、等级与局限

  • 证据类型:前瞻性研究
  • 作者认为加热CRRT治疗液可有效降低AKI患者CRRT期间低体温发生率
  • 局限:原文未报告局限性

对床旁实践的改变

  • 作者认为加热CRRT治疗液可有效降低AKI患者CRRT期间低体温发生率;对合并休克、使用中高剂量血管活性药(中剂量0.2-0.5 μg×kg-1×min-1,高剂量>0.5 μg×kg-1×min-1)、CRRT治疗剂量较高或采用反向管路加热的患者,CRRT期间低体温风险更高,需注意体温监测
  • 原文未据此给出推荐

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To investigate the incidence and risk factors of hypothermia in patients with acute renal injury (AKI) receiving continuous renal replacement therapy (CRRT), and to compare the effects of different heating methods on the incidence of hypothermia in patients with CRRT.

METHODS: A prospective study was conducted. AKI patients with CRRT who were admitted to the department of critical care medicine of the First Affiliated Hospital of Wannan Medical College (Yijishan Hospital) from January 2020 to December 2022 were enrolled as the study subjects. Patients were divided into dialysate heating group and reverse-piped heating group according to randomized numerical table method. Both groups were provided with reasonable treatment mode and parameter setting by the bedside physician according to the patient's specific condition. The dialysis heating group used the AsahiKASEI dialysis machine heating panel to heat the dialysis solution at 37 centigrade. The reverse-piped heating group used the Barkey blood heater from the Prismaflex CRRT system to heat the dialysis solution, and the heating line temperature was set at 41 centigrade. The patient's temperature was then continuously monitored. Hypothermia was defined as a temperature lower than 36 centigrade or a drop of more than 1 centigrade from the basal body temperature. The incidence and duration of hypothermia were compared between the two groups. Binary multivariate Logistic regression analysis was used to explore the influencing factors of hypothermia during CRRT in AKI patients.

RESULTS: A total of 73 patients with AKI treated with CRRT were eventually enrolled, including 37 in the dialysate heating group and 36 in the reverse-piped heating group. The incidence of hypothermia in the dialysis heating group was significantly lower than that in the reverse-piped heating group [40.5% (15/37) vs. 69.4% (25/36), P < 0.05], and the hypothermia occurred later than that in the reverse-piped heating group (hours: 5.40±0.92 vs. 3.35±0.92, P < 0.01). Patients were divided into hypothermic and non-hypothermic groups based on the presence or absence of hypothermia, and a univariate analysis of all indicators showed a significant decrease in mean arterial pressure (MAP) in hypothermic patients (n = 40) compared with the non-hypothermic patients [n = 33; mmHg (1 mmHg ≈ 0.133 kPa): 77.45±12.47 vs. 94.42±14.51, P < 0.01], shock, administration of medium and high doses of vasoactive drug (medium dose: 0.2-0.5 μg×kg-1×min-1, high dose: > 0.5 μg×kg-1×min-1) and CRRT treatment were significantly increased [shock: 45.0% (18/40) vs. 6.1% (2/33), administration of medium and high doses of vasoactive drugs: 82.5% (33/40) vs. 18.2% (6/33), administration of CRRT (mL×kg-1×h-1): 51.50±9.38 vs. 38.42±10.97, all P < 0.05], there were also significant differences in CRRT heating types between the two groups [in the hypothermia group, the main heating method was the infusion line heating, which was 62.5% (25/40), while in the non-hypothermia group, the main heating method was the dialysate heating, which was 66.7% (22/33), P < 0.05]. Including the above indicators in a binary multivariate Logistic regression analysis, it was found that shock [odds ratio (OR) = 17.633, 95% confidence interval (95%CI) was 1.487-209.064], mid-to-high-dose vasoactive drug (OR = 24.320, 95%CI was 3.076-192.294), CRRT heating type (reverse-piped heating; OR = 13.316, 95%CI was 1.485-119.377), and CRRT treatment dose (OR = 1.130, 95%CI was 1.020-1.251) were risk factors for hypothermia during CRRT in AKI patients (all P < 0.05), while MAP was protective factor (OR = 0.922, 95%CI was 0.861-0.987, P < 0.05).

CONCLUSIONS: AKI patients have a high incidence of hypothermia during CRRT treatment, and the incidence of hypothermia can be effectively reduced by heating CRRT treatment fluids. Shock, use of medium and high doses of vasoactive drug, CRRT heating type, and CRRT treatment dose are risk factors for hypothermia during CRRT in AKI patients, with MAP is a protective factor.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Zhang P, Jiang H, Ye X, et al. [Analysis of the incidence and related factors of hypothermia in patients with continuous renal replacement therapy]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2023. PMID: 37308194. doi:10.3760/cma.j.cn121430-20221130-01041

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。